STAA

STAAR Surgical Co. 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for STAAR Surgical Company for the period ended September 28, 2007. STAAR develops and manufactures visual implants and ophthalmic products, primarily intraocular lenses (IOLs) for cataract surgery and the Visian ICL for refractive correction. The company operates globally with manufacturing sites in the U.S. and Switzerland.

Key Financial Metrics

Liquidity & Debt: The company holds $14.2 million in cash. Notes payable were fully repaid during the period. Capital lease obligations total $2.16 million ($0.86 million current, $1.31 million long-term). A $4.0 million cash payment is due for the acquisition of the remaining interest in the Canon Staar joint venture.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 2.4% for the quarter and 4.7% for the nine-month period compared to 2006. International sales grew 16.9% (quarter) and 16.6% (nine months), driven by refractive products (ICL/TICL) and favorable currency effects.
• U.S. Sales Decline: U.S. sales decreased 16.9% for the quarter and 12.2% for the nine months. This decline is attributed to reduced cataract sales and slower-than-expected growth in U.S. refractive sales.
• Margin Expansion: Gross profit margins improved to 49.7% (quarter) and 49.0% (nine months) from 47.6% and 47.3% in the prior year, primarily due to a higher mix of high-margin refractive sales.
• Expense Increases: Operating expenses rose significantly. Marketing and selling expenses increased 13.5% (quarter) due to higher headcount and travel. General and administrative expenses increased 10.4% (quarter) due to costs associated with the Domilens investigation and credit line termination.
• Capital Raise: In May 2007, the company completed a public offering of 3.6 million shares, raising approximately $16.6 million in net proceeds.

Outlook, Risks, and Contingencies

• Canon Staar Acquisition: On October 25, 2007, STAAR agreed to acquire the remaining 50% interest in its joint venture, Canon Staar, for $4 million cash and 1.7 million shares of Series A Convertible Preferred Stock. Closing is expected by December 28, 2007, subject to conditions.
• FDA Regulatory Issues: The FDA placed the company's application for the Toric ICL (TICL) on "integrity hold" in August 2007 due to compliance deficiencies in clinical study documentation. An independent third-party audit is required before resubmission, likely delaying approval.
• Internal Control Weakness: Management identified a material weakness in internal controls related to the German subsidiary (Domilens), stemming from the misappropriation of assets by the former president. Remediation efforts are ongoing, and disclosure controls were deemed ineffective as of the period end.
• Legal Proceedings: Two former regional representatives (Moody and Parallax) filed lawsuits claiming interference with contracts, seeking $32 million and $48 million in damages respectively. STAAR believes the claims are without merit and has not accrued expenses.
• Sales Force Restructuring: The company is transitioning from independent regional representatives to a direct sales force in the U.S. to better support refractive and cataract product lines, a move that carries execution risk.

Investor Verification Checklist

• Verify the status of the FDA "integrity hold" on the TICL application and the timeline for the independent audit.
• Monitor the progress of the Canon Staar buy-out closing conditions and the impact of the $4 million cash outflow on liquidity.
• Assess the effectiveness of the new direct sales force in reversing the decline in U.S. cataract and refractive sales.
• Review the remediation plan for the material weakness in internal controls regarding the German subsidiary.
• Track the outcome of the pending litigation with former regional representatives (Moody and Parallax).